OrganOx, an organ medical technology company, completed a $142 million primary and secondary equity financing to accelerate growth opportunities for its metra platform technology in the large and high growth organ technology global market. The oversubscribed round was led by new investor HealthQuest Capital with support from existing OrganOx investors BGF and Lauxera Capital Partners, along with additional new investors Sofina, Soleus Capital and Avidity Partners. Existing OrganOx investors include the University of Oxford, Technikos, the Oxford Technology and Innovations Fund and Longwall Ventures.
“Organ disease and failure represent a large unmet need in healthcare, and we are excited to partner with HealthQuest Capital and the outstanding investor syndicate to work together to improve patient care and outcomes,” Oern R. Stuge, executive chairman at OrganOx, said.
“We’re thrilled to back OrganOx as they advance a technology platform that successfully addresses the quadruple aim of healthcare, benefitting patients, healthcare providers and global societal health, in a manner that is cost-neutral to the standard of care,” Garheng Kong, founder and managing partner at HealthQuest Capital, said.
“OrganOx’s financial profile is unparalleled, and partnering with leading investors in this transaction – new and existing – further strengthens us to support the success of our current customers, to expand our customer base and to enter new markets,” Steve Deitsch, chief financial officer at OrganOx, said.
“BGF is proud of our investment in OrganOx and its tremendous performance since our first investment in 2019, and we are pleased to invest in the company again, together with the impressive group of assembled investors,” Tim Rea, co-head of early stage at BGF, said.
“It has been a privilege putting this distinctive syndicate of healthcare specialist investors together,” Samuel Levy, founding partner at Lauxera Capital Partners, said. “We have the technology, team and financial firepower to drive the company’s next chapter.”
Piper Sandler acted as exclusive financial advisor and Latham & Watkins acted as legal counsel to OrganOx in this transaction.
